急性肾损伤时用特异性抗Xa因子水平指导口服Xa抑制剂向静脉肝素转换
本文为3例急性肾损伤患者病例系列,患者正在服用阿哌沙班或利伐沙班,通过监测特异性抗Xa因子水平指导向静脉肝素输注的转换。管理策略未导致血栓结局,但1例患者发生出血。结论认为特异性抗Xa因子水平有助于此类转换,提供个体化治疗并可能避免抗凝过度或不足。
要点
- 急性肾损伤患者从口服Xa抑制剂转静脉肝素时可监测特异性抗Xa因子水平。
- 病例中分别在阿哌沙班抗Xa水平<50 ng/mL或<100 ng/mL、利伐沙班<100 ng/mL时启动肝素。
- 该策略未导致血栓结局,但1例患者发生出血。
核心结论
- 特异性抗Xa因子水平可能有助于急性肾损伤患者从利伐沙班或阿哌沙班向普通肝素输注的转换。
- 这些水平提供增强的个体化治疗,并可能帮助避免抗凝过度或不足。
研究设计与样本
- 病例系列,共3例急性肾损伤患者,正在服用阿哌沙班或利伐沙班并转换为肝素输注。
主要发现
- 病例1为78岁男性,因呼吸衰竭、急性失代偿性心衰和急性肾损伤入院,服用阿哌沙班治疗心房扑动,转换后连续2次肝素抗Xa因子水平大于2 units/mL,停用肝素约36小时后阿哌沙班抗Xa水平小于50 ng/mL时恢复。
- 病例2为55岁男性,因急性肾损伤入院,服用阿哌沙班治疗近期深静脉血栓,监测阿哌沙班抗Xa水平,在末次阿哌沙班剂量后约56小时水平小于100 ng/mL时启动静脉肝素。
- 病例3为64岁女性,因脓毒症和急性肾损伤入院,服用利伐沙班治疗入院前2周发生的肺栓塞,监测利伐沙班抗Xa水平,在末次剂量后约36小时水平小于100 ng/mL时启动静脉肝素。
- 管理策略未导致任何血栓结局,但1例患者发生出血。
关键数值与推荐
- 病例1中肝素抗Xa因子水平大于2 units/mL时停用肝素,阿哌沙班抗Xa水平小于50 ng/mL时恢复肝素。
- 病例2中阿哌沙班抗Xa水平小于100 ng/mL时启动静脉肝素。
- 病例3中利伐沙班抗Xa水平小于100 ng/mL时启动静脉肝素。
临床怎么用
- 在急性肾损伤患者需从口服Xa抑制剂转换为静脉肝素时,可考虑监测特异性抗Xa因子水平以指导启动时机。
- 根据抗Xa因子水平个体化调整肝素启动,可能减少抗凝过度或不足的风险。
局限性
- 仅为3例病例系列,样本量小,结果需更大规模研究验证。
- 1例患者发生出血,提示该策略仍需谨慎评估出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This case series presents 3 patients with acute kidney injury taking apixaban or rivaroxaban and transitioning to a heparin infusion. SUMMARY: Case 1 was a 78-year-old man admitted with respiratory failure, acute decompensated heart failure, and acute kidney injury. He was taking apixaban for atrial flutter. He was transitioned to an i.v. heparin infusion and had 2 consecutive heparin antifactor-Xa levels greater than 2 units/mL. Heparin was held and resumed about 36 hours later when the apixaban anti-Xa level was less than 50 ng/mL. Case 2 was a 55-year-old man admitted with acute kidney injury, taking apixaban for a recent deep vein thrombosis. Apixaban anti-Xa levels were monitored and i.v. heparin was initiated when the level was less than 100 ng/mL, about 56 hours after the last apixaban dose. Case 3 was a 64-year-old woman admitted with sepsis and acute kidney injury taking rivaroxaban for pulmonary embolism, which occurred 2 weeks prior to admission. Rivaroxaban anti-Xa levels were monitored and i.v. heparin was initiated about 36 hours after the last dose when the level was less than 100 ng/mL. The management strategy did not lead to any thrombotic outcomes; however, 1 patient experienced bleeding. CONCLUSION: Specific anti-Xa levels for rivaroxaban and apixaban appeared to be helpful in the transition of 3 patients to unfractionated heparin infusions in the setting of acute kidney injury. These levels provided enhanced, individualized care and likely helped avoid over and under anticoagulation.
引用
- Zochert S, Oltman KM, Elgersma BM, et al. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion. Am J Health Syst Pharm. 2019. PMID: 31361865. doi:10.1093/ajhp/zxz013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。